phrykt

Xilio Therapeutics, Inc. (XLO): who owns it and who trades it

As of Nov 16, 2026, XLO insiders reported 2 open-market sales worth $5.7K and 1 purchase worth $43.9K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Christopher James Frankenfield (CFO), with $4.5K. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Xilio Therapeutics

From the latest filings

Overall: more selling than buying. Insiders and famous investors mostly sold. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns XLO

25 funds and institutions reported XLO shares worth $26.4M at the end of Q2 2026, about 48% of the company. The largest holder is Bain Capital Life Sciences Investors, LLC with 11.5%.

Funds and institutions (13F) 48%Everyone else 52%

10 largest owners, by share of the company

Bain Capital Life Sciences Investors, LLC11.5%
Orbimed Advisors LLC10.2%
Frazier Life Sciences Management, L.P.7.3%
Stonepine Capital Management, LLC3.9%
Vanguard Capital Management LLC3.1%
Sio Capital Management, LLC2.6%
Adage Capital Partners Gp, L.l.c.1.9%
Merck & Co., Inc.1.8%
Renaissance Technologies LLC1.1%
Morgan Stanley1.0%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Bain Capital Life Sciences Investors, LLC664,02111.48%$6.4MNo change
Orbimed Advisors LLC592,30010.24%$5.7MNew
Frazier Life Sciences Management, L.P.422,5057.31%$4MNo change
Stonepine Capital Management, LLC225,9943.91%$2.2M+252%
Vanguard Capital Management LLC178,5173.09%$1.7M+44%
Sio Capital Management, LLC152,4642.64%$1.5MNo change
Adage Capital Partners Gp, L.l.c.111,5411.93%$1.1MNew
Merck & Co., Inc.105,9821.83%$1MNo change
Renaissance Technologies LLC64,1531.11%$615K+29%
Morgan Stanley56,9540.98%$546K-1%
Geode Capital Management, LLC39,0550.68%$374K+5%
Citadel Advisors LLC25,9500.45%$249KNew
Vanguard Fiduciary Trust Co22,5940.39%$216K-21%
Bridgeway Capital Management, LLC17,5440.30%$168KNew
Two Sigma Investments, LP14,5440.25%$139KNew
Velan Capital Investment Management LP14,2850.25%$137KNo change
Gsa Capital Partners LLP13,5900.24%$130K-20%
State Street Corp13,3110.23%$128KNo change
Prelude Capital Management, LLC11,6000.20%$111KNew
BlackRock, Inc.8,7570.15%$83.9KNew

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, XLO insiders reported $43.9K of open-market purchases and $5.7K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$43.9K
1 trades, 1 people
Sales, 12 months
$5.7K
2 trades, 2 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Mar 26, 2026
Filed Mar 30, 2026

Purchases and sales by month

$43.9K$43.9KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Mar 26, 2026James Samuel ShannonDirectorPurchase5,000$8.79$43.9KForm 4
Jan 2, 2026Kevin M. BrennanVice presidentSale1,826$0.64$1.2KForm 4
Jan 2, 2026Christopher James FrankenfieldCFOSale7,030$0.64$4.5KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
James Samuel ShannonDirector$43.9K–Mar 26, 2026
Christopher James FrankenfieldChief Financial Officer–$4.5KJan 2, 2026
Kevin M. BrennanSVP, FINANCE AND ACCOUNTING–$1.2KJan 2, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

XLO short interest

382,761 XLO shares are sold short. Over the last 12 reports the number of shares short went up 123%.

As of Oct 30, 2026, 382,761 XLO shares were sold short, down 4.4% from the report before. At the average daily volume of 18,852 shares, buying them all back would take about 20.3 trading days (days to cover).

Shares short, % of all shares

7.09%May 15Sep 308.04%

Days to cover

20.3May 15Oct 3050.9

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 2026382,761–-4%18,85220.3
Oct 15, 2026400,316–-2%9,72741.2
Sep 30, 2026410,0507.09%-1%9,21044.5
Sep 15, 2026412,9637.14%-1%11,05537.4
Aug 31, 2026418,2777.23%-1%10,70539.1
Aug 14, 2026421,9217.30%-1%13,34031.6
Jul 31, 2026425,8827.37%+59%34,68012.3
Jul 15, 2026268,1804.64%+54%59,3494.5
Jun 30, 2026174,6193.02%+1%47,8683.6
Jun 15, 2026173,4703.00%+5%24,4587.1
May 29, 2026165,2742.86%-4%30,4655.4
May 15, 2026171,3702.96%+5%95,0331.8

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Xilio Therapeutics company events

Xilio Therapeutics filed 13 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Nov 10, 2026.

  1. Nov 10, 2026ResultsReleased financial results. Filing
  2. Aug 12, 2026ResultsReleased financial results. Filing
  3. Jun 12, 2026LeadershipIn order to achieve a more equal balance of director membership among the three classes of the board of directors of Xilio Therapeutics, Inc. in accordance with the Company’s Restated Certificate of Incorporation, as amended, following his re-election as a Class II director at the Company’s 2026… Filing
  4. May 12, 2026ResultsReleased financial results. Filing
  5. Apr 16, 2026LeadershipThe Board of Directors of Xilio Therapeutics, Inc., on the recommendation of the Nominating and Corporate Governance committee of the Board, elected Cheryl R. Blanchard, Ph.D., as a Class III director of the Company, with a term expiring at the Company's 2027 annual meeting of stockholders, to… Filing
  6. Mar 23, 2026ResultsReleased financial results. Filing
  7. Mar 12, 2026SharesChanged the rights of its shareholders. Filing
  8. Mar 9, 2026AnnouncementShared information with investors. Filing
  9. Feb 24, 2026VoteReported shareholder vote results. Filing
  10. Feb 12, 2026AgreementXilio Therapeutics, Inc. entered into an underwriting agreement with Leerink Partners LLC, as representative of the underwriter named therein, relating to an underwritten offering of pre-funded warrants to purchase up to 74,780,300 shares of common stock at a price to investors of $0.5349 per… Filing
  11. Jan 8, 2026LeadershipThe Company announced the appointment of Sara M. Bonstein as chair of the Board. Filing
  12. Jan 5, 2026AnnouncementShared information with investors. Filing
  13. Nov 25, 2025LeadershipAt the special meeting of stockholders of Xilio Therapeutics, Inc. held on November 21, 2025, the Company’s stockholders approved the Xilio Therapeutics, Inc. 2025 Stock Incentive Plan, which had previously been adopted by the Company’s Board of Directors subject to stockholder approval. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Xilio Therapeutics financials

Famous investors that hold XLO

2 of the 50 well-known investors we track reported holding XLO in their latest 13F filing. The largest position is Jim Simons's, worth $575K.

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 202663,553$575K0.0%-1%
Ken Griffin · Citadel AdvisorsQ3 202611,061$100K0.0%-57%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 8 filings named XLO in the last 120 days.

FiledHolderFormStake
Nov 16, 2026ADAR1 Capital Management, LLC13G9.3%
Nov 16, 2026Logos Global Management LP13G10.0%
Nov 16, 2026Logos Global Management LP13G10.0%
Nov 16, 2026ADAR1 Capital Management, LLC13G9.3%
Nov 13, 2026Coastlands Capital LP13G/A10.0%
Nov 13, 2026Coastlands Capital LP13G/A10.0%
Nov 12, 2026Adage Capital Management, L.P.13G7.1%
Nov 12, 2026Adage Capital Management, L.P.13G7.1%

Questions about Xilio Therapeutics, Inc. (XLO) stock

Who owns the most XLO stock?

The largest reported owner of Xilio Therapeutics, Inc. (XLO) is Bain Capital Life Sciences Investors, LLC, with 11.5% of the company. In total, 25 funds and institutions reported holding XLO at the end of Q2 2026, together about 48% of the shares. See the largest owners.

Are XLO insiders buying or selling?

In the last 12 months, XLO insiders reported 1 open-market purchase worth $43.9K and 2 sales worth $5.7K. The latest trade was on Mar 26, 2026. See every trade.

What is the short interest in XLO?

As of Oct 30, 2026, 382,761 XLO shares were sold short, down 4.4% from the report before. At the average daily volume of 18,852 shares, buying them all back would take about 20.3 trading days (days to cover). See the history.

Which famous investors hold XLO?

2 of the 50 well-known investors we track reported XLO in their latest 13F filing, including Jim Simons, Ken Griffin. The largest position is worth $575K. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.